v3.25.3

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 5,250,929	$ 5,872,767
Advances and deposits on clinical programs and other current assets	2,006,756	2,136,192
Total current assets	7,257,685	8,008,959
Property and equipment (at cost, less accumulated depreciation and amortization)	601,425	541,272
Other assets:
Operating lease right-of-use assets, net	1,078,623	1,117,133
Deposits and other assets	50,000	50,000
Total other assets	1,128,623	1,167,133
Total assets	8,987,733	9,717,364
Current liabilities:
Accounts payable – trade	1,126,826	1,300,026
Other accrued liabilities	2,676,951	3,033,747
Operating lease liabilities - current portion	394,135	452,358
Total current liabilities	4,197,912	4,786,131
Operating lease liabilities - non-current portion	708,097	686,935
Total liabilities	4,906,009	5,473,066
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value (100,000 shares authorized and no shares issued or outstanding at September 30, 2025 and December 31, 2024)
Common stock - $0.01 par value (350,000,000 and 112,500,000 shares authorized at September 30, 2025 and December 31, 2024, respectively); 2,896,275 and 966,714 shares issued at September 30, 2025 and December 31, 2024, respectively; and 2,896,273 and 966,712 shares outstanding at September 30, 2025 and December 31, 2024, respectively)	28,963	9,667
Additional paid-in capital	421,213,171	411,122,863
Accumulated deficit	(417,075,222)	(406,803,044)
Total stockholders’ equity before treasury stock	4,166,912	4,329,486
Treasury stock, at cost (2 shares at September 30, 2025 and December 31, 2024)	(85,188)	(85,188)
Total stockholders’ equity	4,081,724	4,244,298
Total liabilities and stockholders’ equity	$ 8,987,733	$ 9,717,364

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Imunon, Inc. 10-Q